Let us wait to see the 'Independent Expert Report' (IER) on 'fairness' of offer, interested to see how they propose/justify it as 'fair' to ALL RAP SHs considering potential of the data and app in it's present 'operational/marketed' state...
My take/opinion, RAP BoD have no doubt been quietly 'convinced/coerced' by Pfizer's R&D budget/capabilities to 'productise and distribute' the technology-platform/s, meaning their 'reward/s' behind Pfize-doors are likely to be far better (and less transparent) than RAP as a stand-alone listed-entity can ever offer, even in RAP's most 'ambitious upside' use-case scenarios are realised...
Watching, expecting a resounding 'NO' from SH, even if the IER comes back as FAIR...
RAP Price at posting:
11.3¢ Sentiment: Hold Disclosure: Held
